Limoda

Fingolimod, the active ingredient in Limoda, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral tablet for oral administration. It is used as a disease‑modifying therapy for relapsing‑remitting multiple sclerosis in adult patients, helping to reduce the frequency of clinical relapses and delay disability progression.

GNH USA supplies Limoda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is manufactured under GMP conditions. It is distributed through a secure cold‑chain logistics network to ensure product integrity.

Limoda (fingolimod) is an oral disease‑modifying therapy that targets sphingosine‑1‑phosphate receptors to manage multiple sclerosis.

Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and slows disability progression. Maintenance therapy in RRMS: provides long‑term control of disease activity. MRI disease activity: decreases the number of new or enlarging T2 lesions.

Common Side Effects: - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Diarrhoea: occasional loose stools. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial infections. - Cardiac arrhythmia: bradycardia or atrioventricular block. - Macular oedema: visual disturbances requiring ophthalmologic evaluation. - Progressive multifocal leukoencephalopathy: rare but potentially fatal viral infection. - Severe liver injury: marked hepatic enzyme elevation or hepatitis.

Before initiating therapy, clinicians should assess baseline cardiac function and liver enzymes, and review vaccination history.

- Cardiac monitoring: obtain baseline ECG and observe for bradycardia after first dose. - Liver function: check ALT/AST before start and periodically during treatment. - Vaccination status: avoid live vaccines while on therapy. - Pregnancy and lactation: discuss potential risks; use only if benefit outweighs risk. - Concomitant immunosuppression: evaluate infection risk before combining with other immunosuppressants. Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Fingolimod may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fingolimod exposure. - Live vaccines: risk of disseminated infection. - Drugs causing bradycardia (e.g., beta‑blockers): may exacerbate heart‑rate slowing.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise plasma levels. - Antihypertensive agents: monitor blood pressure for additive effects. - Other immunosuppressants (e.g., azathioprine): increased infection risk.